Welcome to our dedicated page for Lakewood-Amedex news (Ticker: LABT), a resource for investors and traders seeking the latest updates and insights on Lakewood-Amedex stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lakewood-Amedex's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lakewood-Amedex's position in the market.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) reported positive in vitro antimicrobial resistance (AMR) data for lead candidate Nu-3, a topical Bisphosphocin class compound for infected diabetic foot ulcers (iDFU). In 21-day serial‑passage studies, Nu-3 showed only slight MIC increase for E. coli and no MIC change for MRSA, while ciprofloxacin controls rose >2,000-fold (E. coli) and >600-fold (MRSA). Nu-3 retained activity against ciprofloxacin‑resistant isolates, supporting a low potential for resistance development and broad-spectrum activity against resistant pathogens.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) announced its common stock began trading on the Nasdaq Capital Market on April 23, 2026 under the ticker LABT. The company is a clinical-stage biotechnology developer of the Bisphosphocin® class and named Nu-3 as its lead product for infected diabetic foot ulcers (iDFU).
Management said it plans to initiate a Phase 2a clinical trial in iDFU shortly and cited the large U.S. diabetes population and concerns about antibiotic-resistant bacterial strains as drivers for development.